Could GLP-1s Cause Pharmacy Plan Bottom Lines to Balloon In 2025?
The increasing popularity and expanding use cases of GLP-1 drugs, driven by celebrity endorsements, social media trends, and direct-to-consumer advertising, have created significant demand.
Originally approved for diabetes management and weight loss, GLP-1s are replacing lower-cost alternatives and creating financial strain on pharmacy plans. The market for GLP-1s is expected to grow from $46.7 billion in 2024 to a staggering $471.1 billion by 2032.
In this article in BenefitsPro, RxBenefits’ Chief Pharmacy Officer Mark Campbell explores four key trends that will determine what’s next for GLP-1s and the factors that should be evaluated when designing pharmacy benefits plans and making coverage decisions.
